Branch retinal vein occlusion treated by intravitreal triamcinolone acetonide.

Published on Jan 1, 2005in Eye2.455
· DOI :10.1038/SJ.EYE.6701395
Jb Jonas27
Estimated H-index: 27
(Heidelberg University),
Imren Akkoyun12
Estimated H-index: 12
(Heidelberg University)
+ 2 AuthorsRobert F. Degenring27
Estimated H-index: 27
(Heidelberg University)
Sources
Abstract
To evaluate the effect of intravitreal triamcinolone acetonide on visual acuity in branch retinal vein occlusion. The prospective comparative nonrandomized clinical interventional study included 28 patients (28 eyes) with branch retinal vein occlusion. The study group consisting of 10 consecutive patients received an intravitreal injection of 20–25 mg of triamcinolone acetonide. The control group including 18 patients did not receive an intravitreal injection. The mean follow-up was 8.7±4.4 months. In the study group, mean visual acuity increased significantly (P=0.02) from 0.27±0.11 preoperatively to a best postoperative visual acuity of 0.45±0.27. Visual acuity measurements determined 1 month after the injection were significantly (P=0.027) higher than baseline values. Nine (90%) eyes gained in visual acuity, with six (60%) eyes showing an increase in visual acuity of at least two Snellen lines. In the ischaemic subgroup, visual acuity did not change significantly (0.18±0.18 to 0.13±0.04; P=0.66), while, in the nonischaemic subgroup, visual acuity increased significantly (P=0.012) from the baseline value to the best postoperative measurement (0.29±0.09 to 0.53±0.24). In the control group, baseline visual acuity and best visual acuity during the follow-up did not vary significantly (P=0.27). Comparing the study and control groups with each other, the gain in visual acuity was significantly higher in the study group at 1 month (P=0.016) and 2 months (P=0.012) after baseline. Intravitreal injection of triamcinolone acetonide can increase visual acuity in patients with branch retinal vein occlusion.
📖 Papers frequently viewed together
894 Citations
131 Citations
314 Citations
References60
Newest
#1J B JonasH-Index: 1
#2U Bleyl (Heidelberg University)H-Index: 1
Subretinal or retinal neovascularisation, intravitreal proliferation of non-vascular cells, intraretinal or subretinal oedema, and chronic ocular hypotony have recently been treated by intravitreal injections of steroids such as triamcinolone acetonide.1–3 The diseases included long standing macular oedema due to central retinal vein occlusion, diffuse diabetic macular oedema, exudative age related macular degeneration, proliferative diabetic retinopathy, neovascular glaucoma, proliferative vitr...
15 CitationsSource
#1K. Waheed (University of Nottingham)H-Index: 1
#2Gavin M Orr (University of Nottingham)H-Index: 4
Last. Anwar Zaman (University of Nottingham)H-Index: 4
view all 5 authors...
39 Citations
#1Jb Jonas (Heidelberg University)H-Index: 27
#2Ingrid Kreissig (Heidelberg University)H-Index: 40
Last. Robert F. Degenring (Heidelberg University)H-Index: 27
view all 3 authors...
Purpose To report the clinical outcome of patients undergoing cataract surgery after one or repeated intravitreal injections of triamcinolone acetonide as treatment of intraocular neovascular or oedematous diseases. Methods The interventional clinical case series study included all patients (n=22) who presented with cataract which had progressed after a single or repeated intravitreal injection of 25 mg of triamcinolone acetonide as treatment of exudative age-related macular degeneration (n=18) ...
36 CitationsSource
Coats’ disease or entities like Coats’ disease are characterised by a marked exudative retinal detachment with leakage of peripheral retinal vessels, pronounced subretinal deposition of lipids, and eventual progression to total retinal detachment. In some situations, iris neovascularisation can occur, suggesting an angiogenetic component in the course of the disease. In view of the subretinal exudation from the leaking retinal vessels and the possibly neovascular aspect in the disease process, t...
18 CitationsSource
Abstract Background To evaluate the intraocular concentration of triamcinolone acetonide after intravitreal injection. Methods The prospective clinical interventional case series study included 17 patients who had received a 20 to 25-mg intravitreal injection of triamcinolone acetonide as treatment for exudative age-related macular degeneration, diffuse diabetic macular edema, or retinal vein occlusions. During a secondary intraocular surgery taking place 4.1 weeks to 25.7 months after the intra...
96 CitationsSource
#1Jost B. JonasH-Index: 152
#2Imren AkkoyunH-Index: 12
Last. Robert F. DegenringH-Index: 27
view all 5 authors...
Objective To evaluate the outcome of repeated intravitreal injections of triamcinoloneacetonide for the treatment of exudative age-related macular degeneration. Methods This prospective, comparative nonrandomized clinical interventionalstudy included 13 patients with progressive exudative age-related maculardegeneration with occult, or predominantly occult, subfoveal neovascularization.All patients had shown an increase or stabilization of visual acuity aftera first intravitreal injection of 25 ...
114 CitationsSource
Abstract Purpose To report on the treatment of long-standing sympathetic ophthalmia by intravitreal triamcinolone acetonide. Design Clinical interventional case report. Methods A 47-year-old patient who suffered from sympathetic ophthalmia and who was treated with intensive systemic immunosuppressive therapy received an intravitreal injection of 25 mg of triamcinolone acetonide. Before injection, intraocular pressure ranged between 5 and 8 mm Hg; visual acuity measured 6/20. Results Within the f...
50 CitationsSource
#1Jost B. JonasH-Index: 152
#2Ingrid KreissigH-Index: 40
Last. Robert F. DegenringH-Index: 27
view all 3 authors...
91 CitationsSource
50 CitationsSource
#1Ingrid U. Scott (UM: University of Miami)H-Index: 96
#2Harry W. Flynn (UM: University of Miami)H-Index: 98
Last. Philip J. RosenfeldH-Index: 84
view all 3 authors...
Abstract Purpose To report intravitreal triamcinolone acetonide for idiopathic cystoid macular edema (ICME). Design Interventional case series. Methods Two patients with ICME were treated with intravitreal triamcinolone. Results In one patient, best-corrected acuity was 20/70 before treatment and 20/30 6 months posttreatment in both eyes. Foveal thickness was 606 μm before and 197 μm posttreatment in the right eye and 542 μm before and 190 μm posttreatment in the left eye. In another patient, be...
46 CitationsSource
Cited By143
Newest
Source
Source
#1Rie Osaka (Kagawa University)H-Index: 6
#2Yuki Muraoka (Kyoto University)H-Index: 19
Last. Kiyoshi Suzuma (Kagawa University)
view all 8 authors...
PURPOSE To compare anti-vascular endothelial growth factor (anti-VEGF) monotherapy with anti-VEGF therapy combined with sub-Tenon's capsule injections of triamcinolone acetonide (STTA) in patients with macular edema (ME) associated with branch retinal vein occlusion (BRVO). STUDY DESIGN Retrospective observational study METHODS: This study included 186 eyes: 138 eyes received intravitreal injection of ranibizumab (IVR), and the remaining 48 eyes received IVR combined with STTA therapy. If additi...
1 CitationsSource
#1Cristina NiculaH-Index: 8
#2D NiculaH-Index: 4
Last. Ovidiu CrișanH-Index: 1
view all 5 authors...
Purpose. The purpose of the study was to assess the efficacy of intravitreal dexamethasone implant (IDI: Ozurdex®) injection in eyes with macular edema due to retinal vein occlusion. Material and Method. A retrospective, nonrandomized study was conducted in patients with macular edema (ME) due to retinal vein occlusion (RVO) who undertook intravitreal Ozurdex® as first-line treatment. We performed a complete ocular exam including macular OCT. Results. The mean BCVA (logMar) improved from 0.420.4...
1 CitationsSource
Objective: To determine the frequency of an increase in intraocular pressure (IOP) after intravitreal triamcinolone acetonide (IVTA) in diabetic versus non-diabetic patients with various chorio-retinal disorders. Methods: This prospective, interventional comparative case series was conducted at Isra Postgraduate Institute of Ophthalmology, Al-Ibrahim Eye Hospital, Karachi from May 2012 to April 2014. Two hundred thirty seven eyes of 180 patients were enrolled with 90 patients each in diabetic an...
Source
#1Chang Hwan Lee (DU: Dankook University)
#2Moo Hwan Jang (DU: Dankook University)H-Index: 1
Last. Young Seung Seo (DU: Dankook University)H-Index: 2
view all 3 authors...
Source
#1Mert SimsekH-Index: 3
#2Mehmet CitirikH-Index: 11
Last. Dilara OzkoyuncuH-Index: 1
view all 4 authors...
Purpose: This study evaluated the effect of intravitreal dexamethasone implant (IDI; Ozurdex) injection for treating macular edema in patients with branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO). Methods: This prospective study included 40 eyes of 40 patients with nonischemic BRVO and 31 eyes of 31 patients with nonischemic CRVO who received IDI injection as the first-line treatment for macular edema. The best-corrected visual acuity (BCVA) value before and after t...
1 CitationsSource
#1Alex S. Willoughby (UC Davis: University of California, Davis)H-Index: 3
#2Vivian S. Vuong (UC Davis: University of California, Davis)H-Index: 5
Last. Glenn Yiu (UC Davis: University of California, Davis)H-Index: 21
view all 7 authors...
Purpose To evaluate choroidal and suprachoroidal changes following suprachoroidal injection of triamcinolone acetonide injectable suspension (CLS-TA), in eyes with macular edema due to retinal vein occlusion (RVO). Design Prospective cohort study within a randomized, controlled phase 2 clinical trial. Methods Enhanced depth imaging optical coherence tomography (EDI-OCT) images were analyzed from 38 eyes of 38 treatment-naive patients with macular edema due to RVO, enrolled in the prospective Sup...
28 CitationsSource
#1Young Hee Yoon (UOU: University of Ulsan)H-Index: 30
#2Jong Woo Kim (Konyang University)H-Index: 16
Last. Susan SimonyiH-Index: 1
view all 10 authors...
Purpose: To evaluate the effect of dexamethasone intravitreal implant for macular edema (ME) following branch retinal vein occlusion (BRVO) in Korean patients. Methods: We performed a prospective, open-label, multicenter study of 71 patients with ME for < 3 months. Retreatment was allowed ≥4 months from the last injection. Results: At 6 and 12 months, mean ± SD best-corrected visual acuity (BCVA) improvement was 18.6 ± 12.9 and 15.3 ± 15.0 letters, respectively. Approximately 70% of maximum trea...
16 CitationsSource
view all 4 authors...